Outcomes Associated With Early Initiation and Rapid Uptitration of Heart Failure Therapy in HF W

10 Mar 20266 min read0 viewsJournal Feed

GIST

In this Swedish real-world analysis of 6,847 patients with heart failure and left ventricular ejection fraction <50%, investigators compared low versus medium/optimal guideline-directed medical therapy (GDMT) doses at initiation and follow-up. Using data from the Swedish Heart Failure Registry linked to national health registries, the study assessed all-cause and cardiovascular (CV) mortality at 3, 12, and 24 months, with inverse probability weighting to adjust for treatment selection.

At 24 months, medium/optimal GDMT was associated with a lower risk of death: all-cause mortality fell by 23% (adjusted HR 0.77; 95% CI 0.67–0.90; P<0.001) and CV mortality fell by 24% (adjusted HR 0.76; 95% CI 0.62–0.93; P=0.008) compared with low-dose therapy. Benefits emerged as early as 3 months, though adjusted analyses did not show statistical significance at that time point.

The findings are consistent with the STRONG-HF trial and support rapid uptitration of GDMT in routine practice when feasible. Limitations include the observational design and potential residual confounding inherent to registry-based studies.

Clinical Editorial

Early real-world signal of benefit from GDMT uptitration

Participants were split into two cohorts based on GDMT dose: low dose versus medium/optimal dose.

Study scope and design: Retrospective analysis using the Swedish Heart Failure Registry linked to national health registries, focusing on patients with newly diagnosed heart failure and ejection fraction <50%.
Population and timeframe: 6,847 patients included, with follow-up outcomes assessed at 3, 12, and 24 months.

Major mortality findings for real-world GDMT dosing

All-cause mortality: By 24 months,Medium/optimal GDMT was associated with a 23% relative reduction in all-cause mortality compared with low-dose therapy (adjusted hazard ratio 0.77; 95% CI 0.67–0.90; P<0.001).
Cardiovascular mortality: By 24 months, a 24% relative reduction in cardiovascular mortality was observed with medium/optimal GDMT (adjusted hazard ratio 0.76; 95% CI 0.62–0.93; P=0.008).
Time to signal: Mortality benefits appeared as early as 3 months, but significance after adjustment for confounders was not sustained at that early time point.

Context within prior trials and practice implications

Alignment with prior data: Findings are consistent with the STRONG-HF trial, supporting rapid GDMT uptitration in routine practice.
Practical insight: The results support early and aggressive titration of guideline-directed medical therapy in patients with HFrEF to reduce mortality risk over 12–24 months.

Limitations and interpretation caveats

Observational limitations: Despite adjustment using inverse probability weighting, residual confounding cannot be ruled out.
Generalizability: Findings are derived from registry data within Sweden and may reflect local practice patterns; applicability to different healthcare settings should be considered with caution.

Operational and research considerations

Emphasis on early optimization: The study reinforces the potential survival advantages of initiating GDMT promptly and advancing to medium/optimal doses in eligible patients.
Open questions: Details on tolerability, adverse events, and exact dose definitions beyond “low” vs “medium/optimal” are not provided in the summary and would benefit from further clarification in the full report.